251 related articles for article (PubMed ID: 28770295)
1. Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis.
Metzger JC; Wollschläger D; Miederer M; Vaupel P; Moehler M; Schmidberger H; Mayer A
Strahlenther Onkol; 2017 Oct; 193(10):791-799. PubMed ID: 28770295
[TBL] [Abstract][Full Text] [Related]
2. Nodal FDG-PET/CT uptake influences outcome and relapse location among esophageal cancer patients submitted to chemotherapy or radiochemotherapy.
Jimenez-Jimenez E; Mateos P; Ortiz I; Aymar N; Roncero R; Gimenez M; Pardo J; Sabater S
Clin Transl Oncol; 2019 Sep; 21(9):1159-1167. PubMed ID: 30661172
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation.
Chen JX; Lu TY; Fang HY; Lin YS; Lee JM
World J Surg; 2020 Jul; 44(7):2323-2331. PubMed ID: 32296872
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
Chang S; Kim SJ
Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy.
Haefner MF; Lang K; Krug D; Koerber SA; Uhlmann L; Kieser M; Debus J; Sterzing F
J Radiat Res; 2015 Jul; 56(4):742-9. PubMed ID: 25907360
[TBL] [Abstract][Full Text] [Related]
6. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
7. The benefit of PET/CT in the diagnosis and treatment of esophageal cancer.
Vomackova K; Neoral C; Aujeský R; Vrba R; Stasek M; Myslivecek M; Formánek R
Rozhl Chir; 2015 Jan; 94(1):8-16. PubMed ID: 25604979
[TBL] [Abstract][Full Text] [Related]
8. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival.
Hegemann NS; Koepple R; Walter F; Boeckle D; Fendler WP; Angele MK; Boeck S; Belka C; Roeder F
Strahlenther Onkol; 2018 May; 194(5):435-443. PubMed ID: 29349603
[TBL] [Abstract][Full Text] [Related]
10. Radiation field size and dose determine oncologic outcome in esophageal cancer.
Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
[TBL] [Abstract][Full Text] [Related]
11. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
12. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
[TBL] [Abstract][Full Text] [Related]
13. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
14. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
[TBL] [Abstract][Full Text] [Related]
15. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
16. [Esophageal cancer: outcome according to therapeutic strategy].
Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
Nkhali L; Thureau S; Edet-Sanson A; Doyeux K; Benyoucef A; Gardin I; Michel P; Vera P; Dubray B
Acta Oncol; 2015 Jun; 54(6):909-15. PubMed ID: 25417733
[TBL] [Abstract][Full Text] [Related]
19. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
20. Value of FDG-PET/CT Volumetry After Chemoradiotherapy in Rectal Cancer.
Okuno T; Kawai K; Koyama K; Takahashi M; Ishihara S; Momose T; Morikawa T; Fukayama M; Watanabe T
Dis Colon Rectum; 2018 Mar; 61(3):320-327. PubMed ID: 29360680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]